While the use of elivaldogene autotemcel (eli-cel; Skysona) gene therapy has demonstrated long-term efficacy in patients with ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $33.17, along ...

Fintel reports that on October 11, 2024, Jefferies initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a Buy ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...

CDK12 loss characterizes a mCRPC subtype. The study demonstrated that CD12 suppresses prostate cancers, and its loss drives ...

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDAInitiated ...

In a recent study, researchers used high-throughput drug screening to identify potential therapeutic targets and novel ...

Beijing Avistone Biotechnology Co., Ltd (also referred to as "Avistone Biotechnology" or "Avistone"), an innovative biotechnology company focused on precision oncology therapeutics, today announced ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase Pim pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.